Labib Peter L, Davidson Brian R, Sharma Ricky A, Pereira Stephen P
UCL Institute for Liver & Digestive Health, Royal Free Hospital Campus, Royal Free Hospital, Pond Street, London, NW3 2QG, UK.
UCL Division of Surgery & Interventional Science, Royal Free Hospital, Pond Street, London, NW3 2QG, UK.
Hepat Oncol. 2017 Oct;4(4):99-109. doi: 10.2217/hep-2017-0014. Epub 2017 Nov 17.
Cholangiocarcinoma is a rare and aggressive malignancy of the biliary tract. Complete surgical resection can be curative, but the majority of patients are diagnosed with advanced disease and usually die within a year of diagnosis. Most deaths are attributable to local disease progression rather than distant metastases, supporting the use of locoregional therapies. There is evidence that locoregional therapies can provide local tumor control resulting in increased survival while avoiding some of the side effects of systemic treatments, increasing potential treatment options for patients who may be unsuitable for systemic palliative treatments. This review considers the evidence for locoregional therapies in cholangiocarcinoma, which can be classified into endoscopic, vascular, percutaneous and radiation oncological therapies. Current guidelines do not recommend the routine use of locoregional therapies due to a lack of prospective data, but the results of ongoing trials are likely to increase the evidence base and impact on clinical practice.
胆管癌是一种罕见且侵袭性强的胆道恶性肿瘤。完整的手术切除可能治愈该病,但大多数患者确诊时已处于晚期,通常在确诊后一年内死亡。大多数死亡归因于局部疾病进展而非远处转移,这支持了局部区域治疗的应用。有证据表明,局部区域治疗可实现局部肿瘤控制,从而提高生存率,同时避免全身治疗的一些副作用,为可能不适合全身姑息治疗的患者增加了潜在的治疗选择。本综述探讨了胆管癌局部区域治疗的证据,这些治疗可分为内镜治疗、血管治疗、经皮治疗和放射肿瘤学治疗。由于缺乏前瞻性数据,目前的指南不建议常规使用局部区域治疗,但正在进行的试验结果可能会增加证据基础并影响临床实践。